Trial of Ovarian Vein and Pelvic Vein Embolization in Women With Chronic Pelvic Pain and Pelvic Varices
Weill Medical College of Cornell University · with Society of Interventional Radiology Foundation, VIVA Physicians · NCT06168058
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–75 · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 40
- US sites recruiting
- 4
- Study start
- October 29, 2025
- Record last updated
- October 16, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to see if a randomized controlled trial of ovarian vein and pelvic vein embolization versus venography alone could determine outcomes for women with chronic pelvic pain and pelvic varicose veins.
The data gathered will assist in addressing changes in quality of life in patients who have ovarian/pelvic vein embolization versus no embolization.
Being studied: Transcatheter Venography; Bilateral ovarian vein embolization
Conditions: Chronic Pelvic Pain Syndrome; Pelvic Pain; Pelvic Varices; Pelvic Congestive Syndrome; Pelvic Pain Syndrome
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Presence of venous origin chronic pelvic pain for greater than 6 months (VAS ≥7 as determined by 4 consecutive weeks of baseline self-assessments) despite non-vascular therapy as delineated by the following criteria:
- Pain exacerbated by walking, standing or lifting
- Symptoms are at least partially alleviated by lying down
- Prolonged post-coital ache
- Absence of non-venous origin CPP as determined by Gynecology examination
- Symptoms-Varices-Pathophysiology Classification18 including of one of the following:
•S2V2PBGV,R,NT, S2V2PRGV,R,NT , S2V2PLGV,R,NT, with or without S2V2 PBIIV,R,NT, S2V2 PLIIV,R,NT, S2V2 PRIIV,R,NT
- CT, TAUS and diagnostic venography (if needed) imaging review for pelvic venous imaging factors
- Left or right ovarian vein diameter greater than or equal to 6 mm as documented by TAUS or CT
- Presence of intrabdominal/pelvic varices as documented by TAUS or CT (≥1 veins, >5 mm diameter)
- Presence of venous reflux in ovarian and/or internal iliac veins without evidence of hemodynamically significant stenosis
Exclusion Criteria
- Female \<18 years of age
- Pregnancy (positive pregnancy test)
- Female subject who plans to become pregnant during study period
- Female subject who is actively breastfeeding
- Patient who is post-menopausal or anovulatory with hormone suppression
- History of prior hysterectomy
- Prior ovarian vein embolization or ovarian vein ligation
- Inability to tolerate endovascular procedure due to acute illness or general health
- Planned simultaneous treatment with nerve blocks during the duration of the study
- Laparoscopy or planned surgical intervention during the duration of the study
- Known allergy to sclerosant, coil, stent or catheter components including nickel allergy
- Any iliac vein stenosis determined identified by the investigator on pelvic DUS, CT venogram, and/or Catheter Venography and deemed significant for exclusion by study patient review committee.
- Any renal vein stenosis with resultant renal hilar varices/collaterals and lumbar collaterals identified by the investigator on pelvic DUS, CT venogram, and/or Diagnostic Venography and deemed significant for exclusion by study patient review committee.
- Presence of isolated extra-pelvic vulvar and/or lower extremity varices without intrabdominal pelvic varices. Primary S3 categorization study exclusion.
- Serious medical conditions that might preclude full participation in the study to the desired endpoint (e.g., uncontrolled diabetes, malignancy, COPD, MI, CHF, etc.)
- Severe allergy to iodinated or gadolinium-based contrast refractory to steroid premedication
- Severe renal impairment (on chronic dialysis or estimated GFR \<30 mL/min)
- Hemoglobin \<8.0 g/dL, uncorrectable INR >3.0 or platelet count \<75,000/microliter
- Inability to provide informed consent or to comply with study assessments
- Post thrombotic IVC, iliac or ovarian vein changes
Recruiting US locations
University of Kansas Medical Center
Kansas City, KS 66160
Site contact: Adam Alli, MD
Northwell Health Physician Partners Vascular Surgery
New Hyde Park, NY 11042
Weill Cornell Medicine
New York, NY 10024
Site contact: Neil K Khilnani, MD
UNC School of Medicine
Chapel Hill, NC 27599
Site contact: Gloria Salazar, MD
Study contacts (from the official record)
- Neil M Khilnani, MD · 646-962-9179 · EMBOLIZE@med.cornell.edu
- Sasha Garcia · sag2958@med.cornell.edu
Similar studies in Kansas
All healthy volunteers studies in Kansas →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
Basilea Pharmaceutica
- Location
- Lenexa, KS
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study of BLB-201 RSV Vaccine in Infants and Children
Blue Lake Biotechnology Inc.
- Location
- Newton, KS + 13 other US sites
- Eligibility basics
- Ages 6 mo–5
- RecruitingHealthy volunteersPhase 1
Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
- Location
- Overland Park, KS
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
A Study of RO7890597 in Healthy Adult Volunteers
Genentech, Inc.
- Location
- Lenexa, KS
- Eligibility basics
- Ages 18–65